These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 36542262)

  • 21. Increased risk of incident diabetes in patients with MAFLD not meeting the criteria for NAFLD.
    Park SH; Park J; Kwon SY; Lee YB; Kim G; Hur KY; Koh J; Jee JH; Kim JH; Kang M; Jin SM
    Sci Rep; 2023 Jul; 13(1):10677. PubMed ID: 37393407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study.
    Han E; Chun HS; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Lee BW; Kang ES; Cha BS; Ahn SH; Kim SU
    J Gastroenterol Hepatol; 2023 Sep; 38(9):1598-1609. PubMed ID: 37321651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
    van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
    JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name.
    Ng CH; Huang DQ; Nguyen MH
    Clin Mol Hepatol; 2022 Oct; 28(4):790-801. PubMed ID: 35545437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.
    Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2023 Apr; 17(2):350-356. PubMed ID: 36471232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prevalence of metabolic dysfunction-associated fatty liver disease and its association on adverse pregnancy outcomes in women with gestational diabetes mellitus.
    Chai TY; Deng D; Byth K; George J; Pasupathy D; Cheung NW
    Diabetes Res Clin Pract; 2022 Sep; 191():110038. PubMed ID: 35970401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiometabolic characterization in metabolic dysfunction-associated fatty liver disease.
    Perdomo CM; Núñez-Córdoba JM; Ezponda A; Mendoza FJ; Ampuero J; Bastarrika G; Frühbeck G; Escalada J
    Front Med (Lausanne); 2022; 9():1023583. PubMed ID: 36341262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups.
    Kim H; Lee CJ; Ahn SH; Lee KS; Lee BK; Baik SJ; Kim SU; Lee JI
    Dig Dis Sci; 2022 Oct; 67(10):4919-4928. PubMed ID: 35579799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between serum 25-hydroxy vitamin D concentrations and mortality among individuals with metabolic dysfunction-associated fatty liver disease: a prospective cohort study.
    Zhang JJ; Yu HC; Li Y; Zhang YB; Geng TT; Lu Q; Liao YF; Guo KQ; Du L; Ruan HL; Yang K; Liu G; Pan A
    Am J Clin Nutr; 2022 Nov; 116(5):1409-1417. PubMed ID: 36107812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NAFLD and MAFLD independently increase the risk of major adverse cardiovascular events (MACE): a 20-year longitudinal follow-up study from regional Australia.
    Vaz K; Kemp W; Majeed A; Lubel J; Magliano DJ; Glenister KM; Bourke L; Simmons D; Roberts SK
    Hepatol Int; 2024 Aug; 18(4):1135-1143. PubMed ID: 39008030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China.
    Yuan X; Wang X; Wu S; Chen S; Wang Y; Wang J; Lu Y; Sun Y; Fu Q; Wang L
    Hepatobiliary Surg Nutr; 2023 Oct; 12(5):671-681. PubMed ID: 37886198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonalcoholic fatty liver disease without overlapping metabolic-associated fatty liver disease and the risk of incident type 2 diabetes.
    Cho Y; Chang Y; Ryu S; Wild SH; Byrne CD
    Liver Int; 2023 Nov; 43(11):2445-2454. PubMed ID: 37387519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population.
    Seo JY; Cho EJ; Kim MJ; Kwak MS; Yang JI; Chung SJ; Yim JY; Yoon JW; Chung GE
    J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2953-2960. PubMed ID: 36222309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic dysfunction-associated fatty liver disease increases the risk of type 2 diabetes mellitus in young Korean adults.
    Ha J; Hong OK; Han K; Kwon HS
    Diabetes Res Clin Pract; 2024 Jun; 212():111584. PubMed ID: 38367650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis.
    Bessho R; Kashiwagi K; Ikura A; Yamataka K; Inaishi J; Takaishi H; Kanai T
    PLoS One; 2022; 17(5):e0269265. PubMed ID: 35639744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic associated fatty liver disease is a risk factor for chronic kidney disease.
    Hashimoto Y; Hamaguchi M; Okamura T; Nakanishi N; Obora A; Kojima T; Fukui M
    J Diabetes Investig; 2022 Feb; 13(2):308-316. PubMed ID: 34561962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
    J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics.
    Song BG; Kang TW; Sinn DH; Kim YY; Min JH; Hwang JA; Shin J
    Clin Imaging; 2024 Apr; 108():110097. PubMed ID: 38310832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.